Legal status · United States
Is Efinopegdutide legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Efinopegdutide is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
Efinopegdutide in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | In clinical development for metabolic liver disease. No approval anywhere. |
| FDA approval status | Investigational. Not approved. Licensed to Merck, originally from Hanmi, and previously carried Johnson and Johnson and Hanmi identifiers. |
| Human studies cited | 3 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Efinopegdutide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Efinopegdutide is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Efinopegdutide is
Beat semaglutide on liver fat in a randomised head to head, cutting it 72.7 percent against 42.3 percent, while the weight difference was not significant. Adding glucagon does something to the liver that GLP-1 alone does not.
Most dual agonists on this site pair GLP-1 with GIP. This one pairs it with glucagon, which sounds wrong to anyone who knows glucagon raises blood sugar, and the logic is worth following.
Mechanism: A co-agonist at the GLP-1 and glucagon receptors, built on a long-acting Fc-based scaffold. GLP-1 receptor agonism reduces food intake and improves glycaemic control in the usual way.
Regulatory history: Investigational. Not approved. Licensed to Merck, originally from Hanmi, and previously carried Johnson and Johnson and Hanmi identifiers.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Efinopegdutide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Efinopegdutide in other countries
Frequently asked questions
Is Efinopegdutide legal in the United States?
No. Efinopegdutide is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile. Note: In clinical development for metabolic liver disease. No approval anywhere.
Can I buy Efinopegdutide in the United States?
No approved product exists to buy. In the United States Efinopegdutide is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: In clinical development for metabolic liver disease. No approval anywhere.
Is Efinopegdutide FDA approved?
No. FDA status: Investigational. Not approved. Licensed to Merck, originally from Hanmi, and previously carried Johnson and Johnson and Hanmi identifiers.. Current US classification: "Investigational, not approved". On the evidence, 3 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Efinopegdutide live on its compound profile.
Efinopegdutide profileThis page is general information about the regulatory status of Efinopegdutide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.